search

Brian Leinwand, PhD

Senior Director, Health Economics and Outcomes Research

A solid dark blue circle, inspired by Barnabie Agatep’s minimalist style, is centered on a light gray background.

Brian provides strategic health economics support throughout a product’s lifecycle and helps clients build evidence packages that demonstrate and support the value of their products.

Brian’s area of specialization is economic modeling, and he has developed models to determine the cost-effectiveness and budget impact of medications and medical devices in a range of therapeutic classes. Brian also supports HEOR focused market access activities, such as conducting evidentiary landscape and gap assessments, as well as mapping out and executing on evidence generation strategies to support and strengthen products’ value propositions.

Additionally, Brian supports clients in advance of, during, and following formal external third-party value assessments to: 1) provide quantitative support in developing or validating comparative effectiveness and cost-effectiveness analyses; and 2) develop strategies aimed at accurately characterizing and articulating their products’ value and optimally positioning them in the healthcare marketplace.

Prior to joining Inovalon, Brian was a senior research scientist with Avalere Health’s HEOR team. Brian also served as a research assistant, at both the University of North Carolina at Chapel Hill and GlaxoSmithKline, and as a health services researcher at Community Care of North Carolina.

Brian has a PhD in pharmaceutical outcomes and policy, an MPH in health policy and management, and a BA in management and society from the University of North Carolina at Chapel Hill.

Connect on LinkedIn
Authored Content
Placeholder
Oncology

Characteristics and Treatment Patterns of Medicare Beneficiaries with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Patients with multiple myeloma (MM) typically relapse or become refractory (RR) to multiple lines/classes of treatment over the course of...

Read More →
Placeholder
Hematology, oncology

Characteristics and Treatment Patterns of Medicare Beneficiaries with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Accepted for presentation at ISPOR 2022. Findings available upon request. Contact us for more information.

Placeholder
Rare disease

Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a U.S. hospital perspective

This study aimed to model the financial impact of caplacizumab with therapeutic plasma exchange (TPE) + immunosuppression for patients experiencing...

Read More →
Placeholder
Neurology

The Mental Health Burden of Patients with Partial Onset Seizures

Accepted for presentation at American Epilepsy Society 2019 Annual Meeting. Findings available upon request. Contact us for more information.

Placeholder
Dermatology, immunology

The Clinical and Economic Impact of Delays in Reimbursement for Select Novel Cancer Therapeutics in Canada, Italy, and Australia

Accepted for presentation at ISPOR Europe 2019 Meeting. Findings available upon request. Contact us for more information.

Placeholder
Economics

A Budget Impact Analysis of Cenobamate for the Treatment of Refractory Partial Epilepsy

Accepted for presentation at International Society for Pharmacoeconomics and Outcomes Research Annual Meeting 2019. Findings available upon request. Contact us for more information.

Share